<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     caa a22        4500</leader>
  <controlfield tag="001">606180354</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20210128100805.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">210128e20150201xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s11136-014-0776-7</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s11136-014-0776-7</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="2">
   <subfield code="a">A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Katy Gallop, Cicely Kerr, Stacey Simmons, Bryan McIver, Ezra Cohen]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Purpose: This study explored the impact of differentiated thyroid cancer (DTC) on health-related quality of life (HRQL) at different treatment phases and evaluated the validity of published DTC utilities and generic health utility measures (EQ-5D and SF-6D) for economic evaluation of treatments for radio-iodine (RAI) refractory DTC. Methods: Focus groups and interviews were conducted with DTC patients grouped by treatment phase. Qualitative thematic analysis was conducted on interview/focus group transcripts. A thematic coding framework was developed to compare experiences between treatment phases and inform development of a conceptual model. Model concepts were mapped to EQ-5D and SF-6D domains/items. Results: Eight focus groups and 11 individual interviews were conducted with 52 DTC patients. Fifty symptoms and HRQL concepts were identified. The impact of DTC and DTC treatment on emotional and cognitive functioning was reported across the treatment phases. The impact on daily activities, mobility, and energy levels was greatest for patients with recurring/persistent or RAI-refractory DTC. Of the 50 concepts, 25 and 27 mapped directly onto domains/items in the EQ-5D and SF-6D, respectively. The SF-6D covered a broader range of DTC impact on emotional/physical problems and daily/social activities than did the EQ-5D. Conclusions: The conceptual model summarizes the wide-ranging impact of DTC and its treatment on patients' HRQL, particularly for those with recurring/persistent or RAI-refractory DTC. Findings suggest that published DTC utilities lack validity for RAI-refractory DTC and that the SF-6D may be more sensitive to HRQL impact of DTC than the EQ-5D.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Springer International Publishing Switzerland, 2014</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Differentiated thyroid cancer</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Radio-iodine refractory</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Health-related quality of life</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Qualitative methods</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Conceptual model</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Health utility</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Gallop</subfield>
   <subfield code="D">Katy</subfield>
   <subfield code="u">ICON Patient Reported Outcomes, Seacourt Tower, West Way, OX2 0JJ, Oxford, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Kerr</subfield>
   <subfield code="D">Cicely</subfield>
   <subfield code="u">ICON Patient Reported Outcomes, Seacourt Tower, West Way, OX2 0JJ, Oxford, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Simmons</subfield>
   <subfield code="D">Stacey</subfield>
   <subfield code="u">Eisai Inc., 100 Tice Blvd., 07677, Woodcliff Lake, NJ, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">McIver</subfield>
   <subfield code="D">Bryan</subfield>
   <subfield code="u">Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
   <subfield code="a">Cohen</subfield>
   <subfield code="D">Ezra</subfield>
   <subfield code="u">University of California San Diego Moores Cancer Center, 3855 Health Sciences Dr., 92093, La Jolla, CA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Quality of Life Research</subfield>
   <subfield code="d">Springer International Publishing</subfield>
   <subfield code="g">24/2(2015-02-01), 325-338</subfield>
   <subfield code="x">0962-9343</subfield>
   <subfield code="q">24:2&lt;325</subfield>
   <subfield code="1">2015</subfield>
   <subfield code="2">24</subfield>
   <subfield code="o">11136</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s11136-014-0776-7</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s11136-014-0776-7</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Gallop</subfield>
   <subfield code="D">Katy</subfield>
   <subfield code="u">ICON Patient Reported Outcomes, Seacourt Tower, West Way, OX2 0JJ, Oxford, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Kerr</subfield>
   <subfield code="D">Cicely</subfield>
   <subfield code="u">ICON Patient Reported Outcomes, Seacourt Tower, West Way, OX2 0JJ, Oxford, UK</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Simmons</subfield>
   <subfield code="D">Stacey</subfield>
   <subfield code="u">Eisai Inc., 100 Tice Blvd., 07677, Woodcliff Lake, NJ, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">McIver</subfield>
   <subfield code="D">Bryan</subfield>
   <subfield code="u">Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">700</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Cohen</subfield>
   <subfield code="D">Ezra</subfield>
   <subfield code="u">University of California San Diego Moores Cancer Center, 3855 Health Sciences Dr., 92093, La Jolla, CA, USA</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Quality of Life Research</subfield>
   <subfield code="d">Springer International Publishing</subfield>
   <subfield code="g">24/2(2015-02-01), 325-338</subfield>
   <subfield code="x">0962-9343</subfield>
   <subfield code="q">24:2&lt;325</subfield>
   <subfield code="1">2015</subfield>
   <subfield code="2">24</subfield>
   <subfield code="o">11136</subfield>
  </datafield>
 </record>
</collection>
